Acquisition by Walter Klemp of 43590 shares of Moleculin Biotech subject to Rule 16b-3
| MBRX Stock | USD 1.88 0.14 8.05% |
Slightly above 54% of Moleculin Biotech's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Moleculin Biotech suggests that some traders are interested. Moleculin Biotech's investing sentiment can be driven by a variety of factors including economic data, Moleculin Biotech's earnings reports, geopolitical events, and overall market trends.
Moleculin |
Filed transaction by Moleculin Biotech Director, Officer: Ceo And President. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Moleculin Biotech Fundamental Analysis
We analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Moleculin Biotech is currently under evaluation in target price category among its peers.
Moleculin Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Moleculin Biotech stock to make a market-neutral strategy. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics with similar companies.
Peers
Moleculin Biotech Related Equities
| ATXI | Avenue Therapeutics | 5.71 | ||||
| CYCC | Cyclacel Pharmaceuticals | 2.86 | ||||
| NXTC | NextCure | 2.60 | ||||
| BPTH | Bio Path | 2.44 | ||||
| ALLR | Allarity Therapeutics | 1.94 | ||||
| VRAX | Virax Biolabs | 1.87 | ||||
| ANTX | AN2 Therapeutics | 1.60 | ||||
| CAPR | Capricor Therapeutics | 1.48 | ||||
| AKTX | Akari Therapeutics | 0.83 | ||||
| PMVP | Pmv Pharmaceuticals | 1.44 | ||||
| IKT | Inhibikase Therapeutics | 1.45 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.85 | ||||
| PULM | Pulmatrix | 2.13 |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.